Results 41 to 50 of about 9,493 (159)

Porcine kidney xenotransplantation: From primate models to clinical reality

Animal Models and Experimental Medicine, EarlyView.
In the face of a critical shortage of human donor kidneys for end‐stage renal disease patients, porcine kidney xenotransplantation has emerged as a viable solution. This field has navigated major hurdles, including immune rejection, physiological incompatibilities, potential biomechanical differences and the risk of cross‐species infection. To overcome
Zihang Guo, Ling Zhang, Shoulong Deng, Chuan Qin   +3 more
wiley   +1 more source

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest, Simon E. Koele, Nicole C. A. J. van de Kar, Saskia M. C. Langemeijer, Rob ter Heine   +4 more
wiley   +1 more source

Eculizumab as Additional Rescue Therapy in Myasthenic Crisis

Muscles
Eculizumab is a monoclonal antibody blocking the terminal complement protein C5. As demonstrated in the phase III randomized, placebo-controlled, REGAIN clinical trial, eculizumab is efficacious in acetylcholine receptor antibody (AChR-Ab)-positive ...
Francesco Crescenzo, Mattia Zanoni, Laura Ferigo, Francesca Rossi, Matteo Grecò, Angelica Lupato, Alessandra Danese, Domenico Ajena, Michelangelo Turazzini   +8 more
doaj   +1 more source

Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

EClinicalMedicine, 2020
Background: Complement pathway inhibition may provide benefit for severe acute respiratory illnesses caused by viral infections such as COVID-19. We present results from a nonrandomized proof-of-concept study of complement C5 inhibitor eculizumab for ...
Djillali Annane, Nicholas Heming, Lamiae Grimaldi-Bensouda, Véronique Frémeaux-Bacchi, Marie Vigan, Anne-Laure Roux, Armance Marchal, Hugues Michelon, Martin Rottman, Pierre Moine   +9 more
doaj   +1 more source

Analysis of Costs per Responder in US Adults with Paroxysmal Nocturnal Hemoglobinuria with a Suboptimal Response to Prior Eculizumab Treatment

Hematology Reports, 2023
European Society for Blood and Marrow Transplantation (EBMT) hematologic response categories comprehensively assess complement inhibitor responses in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Jesse Fishman, Seri Anderson, Sandra E. Talbird, David Dingli   +3 more
doaj   +1 more source

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor, Takanobu Nadai, Kei Irie, Wen Rui Tan, Sanjana Parikh, Anhar Hosawi, Matthijs W. van Hoogdalem, Ronaldo Morales Junior, Sonya Tang Girdwood, Abbie D. Leino, Kana Mizuno, Alexander A. Vinks, Tomoyuki Mizuno   +12 more
wiley   +1 more source

Analysis of the Recovery of Immune Status in the Patients With Paroxysmal Nocturnal Hemoglobinuria After Treatment With C5 Complement Inhibitor

Journal of Clinical Laboratory Analysis, EarlyView.
We retrospectively evaluated the impact of C5 complement inhibition on immune cell profiles and recovery in 27 PNH patients; both CD4+ and CD8+ T cells exhibited partial recovery, while B cell counts increased but remained below normal levels. In contrast, Treg cells were significantly reduced in PNH patients and showed no notable change post‐treatment.
Hui Liu, Mengting Che, Liyan Li, Honglei Wang, Chaomeng Wang, Junshu Wu, Yingying Chen, Zhaoyun Liu, Lijuan Li, Rong Fu   +9 more
wiley   +1 more source

US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization

Drugs - Real World Outcomes
Background and Objective The terminal complement inhibitor eculizumab is approved in the USA for the treatment of patients with acetylcholine receptor antibody-positive generalized myasthenia gravis (MG).
Richard J. Nowak, Ali A. Habib, Andrew J. Klink, Srikanth Muppidi, Anju Parthan, S. Chloe Sader, Alexandrina Balanean, Ajeet Gajra, James F. Howard, ELEVATE Study Group   +9 more
doaj   +1 more source

Eccrine Squamous Syringometaplasia Mimicking Acute Cutaneous GVHD in a Pediatric HSCT Recipient: Case Report and Brief Review of the Indexed Literature

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Eccrine squamous syringometaplasia (ESS) is an uncommon reactive alteration of eccrine ducts, most often reported in oncologic and transplant settings, where it may clinically mimic acute cutaneous graft‐versus‐host disease (GVHD). We describe a 3‐year‐old boy with chronic granulomatous disease who developed a diffuse erythematous eruption 6 ...
Benedetta Galli, Cecilia Catapano, Iacopo Ghini, Mariateresa Rossi, Marina Venturini, Valeria Boccaletti   +5 more
wiley   +1 more source

Thrombotic microangiopathy after kidney transplantation successfully treated with eculizumab: A case report

Transplantation Reports, 2018
Background: Transplantation-associated thrombotic microangiopathy (TA-TMA) is relatively rare and may cause graft failure. Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the alternative complement pathway, resulting in TMA ...
Tomoko Kawanishi, Jumpei Hasegawa, Momoko Kono, Ayumi Ishiwatari, Toshie Ogawa, Yasutomo Abe, Mariko Endo, Hidetoshi Ishigooka, Masayoshi Okumi, Kazunari Tanabe, Sachiko Wakai, Hiroki Shirakawa   +11 more
doaj   +1 more source